Will AstraZeneca’s new strategy make the share price soar?

A pivot to cancer treatment has been profitable for AstraZeneca plc (LON:AZN), but can it last?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shareholders of AstraZeneca (LSE: AZN) have been on a bumpy ride these last six months, with the stock price bouncing between the 5,000p and 6,500p marks. Back in February, the company reported excellent operating results for the fourth quarter of the previous year, showing robust sales growth and earnings that exceeded analyst expectations.

However, since topping out in late March, shares are down more than 10%. Is this an opportunity for investors to get in on a pullback? Let’s dive into it.

Bestselling cancer drugs driving sales

Over the last few years, AstraZeneca has been increasingly focused on developing its oncology pipeline. Most notably, lung cancer drug Tagrisso has the potential to achieve blockbuster status. It has already become AstraZeneca’s best-selling drug, constituting 9% of total product sales at around £1.4 billion in 2018. Moreover, the drug is still a long way away from patent expiry, and some analysts believe that sales could peak at £4.5 billion in 2023. Even if sales fall short of that lofty figure – management’s own number is closer to £2.3 billion – Tagrisso is likely to be a reliable revenue source for AstraZeneca for years going forward.

A long-term strategy

CEO Pascal Soriot deserves a lot of credit for this turnaround. Appointed in 2012, following years of declining sales resulting from a steep patent cliff, he has managed to pivot AstraZeneca towards oncology treatments. This makes sense on two levels. Firstly, given the overall demographic trend of populations getting older, the prevalence of cancer is set to increase. Accordingly, pharmaceutical companies that reposition themselves to cater to this aging world will do comparatively well.

Secondly, AstraZeneca suffered a competitive disadvantage in that many of its older therapies were small-molecule, orally administered drugs that were quite easy to replicate. As a result, the company was hit hard by sales of generics almost as soon as those patents expired. While the conventional view is that patent expiry affects drug company equally, the reality is that makers of generics and biosimilars still need to manufacture the actual product, and so not all generics can undercut prices in the same way.

It’s a tough environment to live in

However, the current regulatory environment has thrown up a number of potential threats to AstraZeneca’s long-term prospects. In particular, the Food and Drug Administration in the USA is increasingly seen to favour lower-cost alternatives to some of the more expensive options. For instance, techniques such as gene editing are being looked at as potentially more cost-effective ways of treating cancer.

Although these technologies are still in relatively early stages, when one considers the fact that drug development takes place over a timescale of decades, it doesn’t seem like such a far-fetched threat. For this reason, I believe AstraZeneca could be vulnerable in the long run.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stepan does not own shares in AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Value Shares

After a 16% drop, FTSE 100 stock JD Sports Fashion looks like a steal to me

This FTSE 100 stock has tanked since mid-September. Edward Sheldon believes that there's value on offer after the share price…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Is now the time to buy BP shares? Here’s what the charts say

The best time to buy shares in a company is when they’re trading at a discount. But the future is…

Read more »

Investing Articles

Here’s how I’d use £50K to aim for a million when the stock market crashes

Seeing a stock market crash as a buying opportunity could prove lucrative for a well-prepared, long-term investor. Christopher Ruane explains…

Read more »

Stack of one pound coins falling over
Investing Articles

It’s up 27% with a P/E of 9! I’m considering the potential of this blossoming penny stock

Despite several years of losses, this UK penny stock has an impressive valuation. I’m looking to see if it could…

Read more »

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »